Update: even more results for IVIG in treating small fiber neuropathy.

In our blog published just last month, we looked at some of the research utilizing intravenous immunoglobulin (IVIG) for small fiber neuropathy (SFN), which occurs when damage to the peripheral nerves predominantly or entirely affects the small myelinated (Aδ) fibers or unmyelinated C fibers. ​

While not necessarily a well-known disorder, SFN does affect roughly four million people globally and can result from diabetes, vitamin B12 deficiency and autoimmune diseases.
 
A recent article featuring Anne Louise Oaklander, MD, PhD in Neurology Reviews takes a closer look at this neurological condition, its clinical presentations and the difficulties in diagnosing what may seem to be a relatively obscure disorder. But SFN is thought to be under-identified as many patients may not consult a neurologist about a wide range of symptoms from pain and itching to fatigue, gastrointestinal issues and more. Add to this the need for expanded assessment tools and physician awareness of the disease and SFN often can be overlooked as a diagnosis.1
 
Dr. Oaklander notes too that for cases originating from an autoimmune cause, another recent study reported on the success of IVIG in providing relief in a large number of research subjects. This is on top of the studies we wrote about that also supports the efficacy of immunotherapy for some SFN patients. 
 
If you would like to learn more about SFN, please be sure to read this excellent piece with Dr. Oaklander’s insights and, as always, don’t hesitate to let us know if you have questions about this or any other neurological concerns. 
 
In health,
Dr. Suzanne Gazda
 
Reference:
1 Oaklander, A.L., Bosworth, T. Small-fiber dysimmune neuropathy emerges as a new treatable disease. Neurology Reviews, April 2021.